Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis

Small GTPases

Volumn 1, Issue 3, 2010, Pages

  Kim, Minjung ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

AKT2; E cadherin; Melanoma; Mouse model; Progression; PTEN; RAS

Indexed keywords

ARF PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GUANINE NUCLEOTIDE BINDING PROTEIN; H RAS PROTEIN; METABOTROPIC RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN N RAS; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; SMALL INTERFERING RNA; STEM CELL FACTOR RECEPTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER INVASION; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; DISEASE MODEL; DISEASE PREDISPOSITION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME DEFICIENCY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE INTERACTION; GENE MUTATION; HUMAN; MELANOMA; METASTASIS POTENTIAL; NONHUMAN; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 79952090075     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.1.3.14344     Document Type: Article

References (44)

1. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006; 355:51-65.
2. Chin L, Garraway LA, Fisher DE. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006; 20:2149-82.
3. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Current protocols in human genetics/editorial board. Jonathan L Haines, et al. 2008; 10:1.
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54.
5. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004; 122:337-41.
6. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. Curr Opin Genet Dev 1997; 7:75-9.
7. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20.
8. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115:813-24.
9. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2007; 129:957-68.
10. Bardeesy N, Kim M, Xu J, Kim RS, Shen Q, Bosenberg MW, et al. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol 2005; 25:4176-88.
11. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163:1765-70.
12. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003; 22:3113-22.
13. Guldberg P, thor Straten P, Birck A, Ahrenkiel V, Kirkin AF, Zeuthen J. Disruption of the MMAC1/ PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 1997; 57:3660-3.
14. Birck A, Ahrenkiel V, Zeuthen J, Hou-Jensen K, Guldberg P. Mutation and allelic loss of the PTEN/ MMAC1 gene in primary and metastatic melanoma biopsies. J Invest Dermatol 2000; 114:277-80.
15. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 2008; 68:664-73.
16. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004; 64:7002-10.
17. Madhunapantula SV, Robertson GP. The PTENAKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009; 22:400-19.
18. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008; 99:1265-8.
19. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, et al. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997; 11:2822-34.
20. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L. Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001; 21:2144-53.
21. Sharpless NE, Kannan K, Xu J, Bosenberg MW, Chin L. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 2003; 22:5055-9.
22. Ackermann J, Frutschi M, Kaloulis K, McKee T, Trumpp A, Beermann F. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res 2005; 65:4005-11.
23. Milagre C, Dhomen N, Geyer FC, Hayward R, Lambros M, Reis-Filho JS, et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010; 70:5549-57.
24. Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, et al. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 2010; 29:5809-17.
25. V600Emice. Oncogene 2009; 28:2289-98.
26. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 2009; 15:294-303.
27. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 2009; 41:544-52.
28. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 2002; 99:1455-60.
29. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400:468-72.
30. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009; 28:151-66.
31. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al. Overexpression of AKT2/ protein kinase Bbeta leads to upregulation of beta1 integrins, increased invasion and metastasis of human breast and ovarian cancer cells. Cancer Res 2003; 63:196-206.
32. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/ neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007; 67:167-77.
33. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126:154-60.
34. Iwanaga K, Yang Y, Raso MG, Ma L, Hanna AE, Thilaganathan N, et al. Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 2008; 68:1119-27.
35. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010; 70:7114-24.
36. Yao D, Alexander CL, Quinn JA, Porter MJ, Wu H, Greenhalgh DA. PTEN loss promotes rasHa-mediated papillomatogenesis via dual upregulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTEN-associated pathways. Cancer Res 2006; 66:1302-12.
37. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000; 60:1800-4.
38. Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, et al. Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 2010; 29:6222-32.
39. Prior IA, Hancock JF. Compartmentalization of Ras proteins. Journal of cell science 2001; 114:1603-8.
40. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998; 273:24052-6.
41. Whitwam T, Vanbrocklin MW, Russo ME, Haak PT, Bilgili D, Resau JH, et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 2007; 26:4563-70.
42. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006; 12:2301-7.
43. Shin SS, Wall BA, Goydos JS, Chen S. AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1). Pigment Cell Melanoma Res 2010; 23:103-11.
44. Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, Tsichlis PN. MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells. Sci Signal 2009; 2:62.